24 June 2026 | 9:05AM HKT Equity Research CARsgen Therapeutics (2171.HK): On-time approval of satri-cel marks the first CAR-T for solid tumor Satri-cel China approval for 3L+ GC: On Jun 22nd, CARsgen announced the approval of satri-cel (CT041, CLDN18.2 CAR-T) by the NMPA for the treatment of patients with Claudin18.2-positive (IHC 2+ ≥40%), HER2-negative advanced gastric/ gastroesophageal junction adenocarcinoma (G/GEJA) who have failed at least two prior lines of therapy, which is based on ph2 China data f ...